Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
20,869,742
-
Share change
-
+1,436,245
-
Total reported value
-
$2,102,944,344
-
Put/Call ratio
-
136%
-
Price per share
-
$100.79
-
Number of holders
-
185
-
Value change
-
+$129,805,908
-
Number of buys
-
96
-
Number of sells
-
78
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q4 2018
As of 31 Dec 2018,
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) was held by
185 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,869,742 shares.
The largest 10 holders included
FMR LLC, BlackRock Inc., Vanguard Group Inc, JPMORGAN CHASE & CO, FIRST TRUST ADVISORS LP, STATE STREET CORP, BOXER CAPITAL, LLC, BB BIOTECH AG, DEUTSCHE BANK AG\, and GOLDMAN SACHS GROUP INC.
This page lists
185
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.